British pharma group praises draft Brexit agreement, but has concerns about drug safety
The UK would remain subject to EMA regulations during a "transition period" to minimize drug supply disruptions, drawing industry praise. But a trade group was also concerned that a draft political declaration could jeopardize drug safety.